Literature DB >> 16825360

Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests.

Matthew P Stevens1, Elice Rudland, Suzanne M Garland, Sepehr N Tabrizi.   

Abstract

Roche Molecular Systems recently released two PCR-based assays, AMPLICOR and LINEAR ARRAY (LA), for the detection and genotyping, respectively, of human papillomaviruses (HPVs). The manual specimen processing method recommended for use with both assays, AmpliLute, can be time-consuming and labor-intensive and is open to potential specimen cross-contamination. We evaluated the Roche MagNA Pure LC (MP) as an alternative for specimen processing prior to use with either assay. DNA was extracted from cervical brushings, collected in PreservCyt media, by AmpliLute and MP using DNA-I and Total Nucleic Acid (TNA) kits, from 150 patients with histologically confirmed cervical abnormalities. DNA was amplified and detected by AMPLICOR and the LA HPV test. Concordances of 96.5% (139 of 144) (kappa=0.93) and 95.1% (135 of 142) (kappa=0.90) were generated by AMPLICOR when we compared DNA extracts from AmpliLute to MP DNA-I and TNA, respectively. The HPV genotype profiles were identical in 78.7 and 74.7% of samples between AmpliLute and DNA-I or TNA, respectively. To improve LA concordance, all 150 specimens were extracted by MP DNA-I protocol after the centrifugation of 1-ml PreservCyt samples. This modified approach improved HPV genotype concordance levels between AmpliLute and MP DNA-I to 88.0% (P=0.043) without affecting AMPLICOR sensitivity. Laboratories that have an automated MP extraction system would find this procedure more feasible and easier to handle than the recommended manual extraction method and could substitute such extractions for AMPLICOR and LA HPV tests once internally validated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825360      PMCID: PMC1489532          DOI: 10.1128/JCM.02608-05

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

2.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.

Authors:  M V Jacobs; P J Snijders; A J van den Brule; T J Helmerhorst; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Different detectability of high-risk HPV in smears from incident and prevalent high-grade squamous intraepithelial lesions of the cervix.

Authors:  A Schneider; D M Zahm; C Greinke; R Kirchmayr; I Nindl
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

4.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.

Authors:  S Y Chan; H Delius; A L Halpern; H U Bernard
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.

Authors:  A J Remmink; J M Walboomers; T J Helmerhorst; F J Voorhorst; L Rozendaal; E K Risse; C J Meijer; P Kenemans
Journal:  Int J Cancer       Date:  1995-05-04       Impact factor: 7.396

Review 7.  Classification of papillomaviruses.

Authors:  Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

8.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

9.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

10.  Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring.

Authors:  Kate S Cuschieri; M J Whitley; Heather A Cubie
Journal:  J Med Virol       Date:  2004-05       Impact factor: 2.327

View more
  15 in total

1.  Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears.

Authors:  Sepehr N Tabrizi; Matthew P Stevens; Zaheer A Khan; Conan Chow; Martin A Devitt; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

2.  Effect of ThinPrep preparation on human papillomavirus detection and genotyping in rectal samples by PCR.

Authors:  Sepehr N Tabrizi; Matthew P Stevens; Marina T van Leeuwen; Claire M Vajdic; Leon P Botes; Gabriele Medley; Richard Hillman; Andrew Grulich; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

3.  Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test.

Authors:  Matthew P Stevens; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

4.  Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital Infection Among Men Who Have Sex With Women: The HPV Infection in Men (HIM) Study.

Authors:  Shitaldas J Pamnani; Alan G Nyitray; Martha Abrahamsen; Dana E Rollison; Luisa L Villa; Eduardo Lazcano-Ponce; Yangxin Huang; Amy Borenstein; Anna R Giuliano
Journal:  J Infect Dis       Date:  2016-08-03       Impact factor: 5.226

5.  Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study.

Authors:  Shitaldas J Pamnani; Staci L Sudenga; Dana E Rollison; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Yangxin Huang; Amy Borenstein; Anna R Giuliano
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

6.  Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.

Authors:  Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

7.  Human papilloma virus genotypes in women from Nayarit, Mexico, with squamous intraepithelial lesions and cervical cancer.

Authors:  Laura Ortega-Cervantes; Adriana Aguilar-Lemarroy; Aurora Elizabeth Rojas-García; Briscia Socorro Barrón-Vivanco; Verónica Vallejo-Ruiz; David Cantú-De León; Yael Yvette Bernal Hernández; Armando Jáuregui-Martínez; Irma Martha Medina-Díaz
Journal:  Int J Health Sci (Qassim)       Date:  2016-07

8.  Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia.

Authors:  Jennifer A Danielewski; Suzanne M Garland; Jenny McCloskey; Richard J Hillman; Sepehr N Tabrizi
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Authors:  Leonardo M Simonella; Hazel Lewis; Megan Smith; Harold Neal; Collette Bromhead; Karen Canfell
Journal:  BMC Infect Dis       Date:  2013-03-03       Impact factor: 3.090

10.  Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence.

Authors:  Alice R Rumbold; Sarah E Tan; John R Condon; Debbie Taylor-Thomson; Maria Nickels; Sepehr N Tabrizi; Margaret L J Davy; Margaret M O'Brien; Christine M Connors; Ibrahim Zardawi; Jim Stankovich; Suzanne M Garland
Journal:  BMC Infect Dis       Date:  2012-10-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.